Abstract
Background: The taxane drugs paclitaxel and docetaxel, widely used on cancer chemotherapy, are currently dosed mainly based on body-surface area. This approach is associated with wide interindividual variability in drug exposure, leading to suboptimal dosing for many patients.
Methods: The available evidence supporting dose individualization strategies for paclitaxel and docetaxel were reviewed, focusing mainly on the application of therapeutic drug monitoring by a priori pharmacogenetic data or a posteriori drug measurements in biological fluids. The PubMed database was searched, in the period of 1987-2017, using the keywords pharmacogenetics, metabolic genotyping, dose individualization, therapeutic drug monitoring, personalized medicine, taxanes paclitaxel and docetaxel, either alone or in combination.
Results: The current knowledge of pharmacology of the taxane drugs paclitaxel and docetaxel, mainly its pharmacokinetics and the proteins responsible for their biotransformation and transport, along with the genetic polymorphism responsible for variations in the activities of these proteins, opens new opportunities for dose selection for individual patients.
Conclusion: Considering the relation between systemic exposure to these drug and clinical responses, a posteriori TDM, with measurement of drug concentrations in plasma of treated patients, is currently the most straightforward approaches for dose individualization of paclitaxel and docetaxel.
Keywords: Pharmacogenetics, metabolic genotyping, dose individualization, therapeutic drug monitoring, personalized medicine, taxanes paclitaxel, docetaxel.
Current Medicinal Chemistry
Title:Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Volume: 24 Issue: 33
Author(s): Natalia B. Andriguetti , Suziane Raymundo, Marina V. Antunes, Magda S. Perassolo, Simone G. Verza, Edna S. Suyenaga and Rafael Linden*
Affiliation:
- Laboratory of Analytical Toxicology, Institute of Health Sciences, Universidade Feevale, Novo Hamburgo-RS,Brazil
Keywords: Pharmacogenetics, metabolic genotyping, dose individualization, therapeutic drug monitoring, personalized medicine, taxanes paclitaxel, docetaxel.
Abstract: Background: The taxane drugs paclitaxel and docetaxel, widely used on cancer chemotherapy, are currently dosed mainly based on body-surface area. This approach is associated with wide interindividual variability in drug exposure, leading to suboptimal dosing for many patients.
Methods: The available evidence supporting dose individualization strategies for paclitaxel and docetaxel were reviewed, focusing mainly on the application of therapeutic drug monitoring by a priori pharmacogenetic data or a posteriori drug measurements in biological fluids. The PubMed database was searched, in the period of 1987-2017, using the keywords pharmacogenetics, metabolic genotyping, dose individualization, therapeutic drug monitoring, personalized medicine, taxanes paclitaxel and docetaxel, either alone or in combination.
Results: The current knowledge of pharmacology of the taxane drugs paclitaxel and docetaxel, mainly its pharmacokinetics and the proteins responsible for their biotransformation and transport, along with the genetic polymorphism responsible for variations in the activities of these proteins, opens new opportunities for dose selection for individual patients.
Conclusion: Considering the relation between systemic exposure to these drug and clinical responses, a posteriori TDM, with measurement of drug concentrations in plasma of treated patients, is currently the most straightforward approaches for dose individualization of paclitaxel and docetaxel.
Export Options
About this article
Cite this article as:
Andriguetti B. Natalia, Raymundo Suziane, Antunes V. Marina , Perassolo S. Magda , Verza G. Simone , Suyenaga S. Edna and Linden Rafael *, Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel, Current Medicinal Chemistry 2017; 24 (33) . https://dx.doi.org/10.2174/0929867324666170623093445
DOI https://dx.doi.org/10.2174/0929867324666170623093445 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Realising the Potential of Adaptive Development of Medicines
Reviews on Recent Clinical Trials Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations
Current Organic Chemistry Clinical and Translational Research Challenges in Neuroendocrine Tumours
Current Medicinal Chemistry Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets Multimodal Nanomedicine Strategies for Targeting Cancer Cells as well as Cancer Stem Cell Signalling Mechanisms
Mini-Reviews in Medicinal Chemistry Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design The Combination of Conventional Chemotherapy with New Targeted Therapy in Hematologic Malignancies: The Safety and Efficiency of Low- Dose Cytarabine Supports its Combination with New Therapeutic Agents in Early Clinical Trials
Current Cancer Therapy Reviews Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases
Reviews on Recent Clinical Trials Do we Need Maintenance Chemotherapy in Advanced NSCLC in the Era of Immune and Targeted Therapy?
Current Cancer Therapy Reviews Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Gene Delivery for Cancer Therapy
Current Drug Delivery Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction
Anti-Cancer Agents in Medicinal Chemistry